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Abstract
Some evidence suggests that Ca and vitamin D supplements affect cancer risk; however, it is uncertain whether the effects are due to Ca,
vitamin D or the combination. We investigated the effect of Ca supplements without co-administered vitamin D on cancer risk. Medline,
Embase and the Cochrane Central Register of Controlled Trials, reference lists of meta-analyses and two clinical trial registries were
searched for randomised, placebo-controlled trials of Ca supplements ($500 mg/d), with $100 participants and duration .1 year. The
lead authors of eligible trials supplied data on cancer outcomes. Trial-level data were analysed using random-effects meta-analyses and
patient-level data using Cox proportional hazards models. A total of sixteen trials were eligible, six had no data available, ten provided
trial-level data (n 10 496, mean duration 3·9 years), and of these, four provided patient-level data (n 7221, median duration 3·5 years).
In the meta-analysis of trial-level data, allocation to Ca did not alter the risk of total cancer (relative risk 0·95, 95 % CI 0·76, 1·18,
P¼0·63), colorectal cancer (relative risk 1·38, 95 % CI 0·89, 2·15, P¼0·15), breast cancer (relative risk 1·01, 95 % CI 0·64, 1·59, P¼0·97)
or cancer-related mortality (relative risk 0·96, 95 % CI 0·74, 1·24, P¼0·75), but reduced the risk of prostate cancer (relative risk 0·54,
95 % CI 0·30, 0·96, P¼0·03), although there were few events. The meta-analysis of patient-level data showed similar results, with no
effect of Ca on the risk of total cancer (hazard ratio 1·07, 95 % CI 0·89, 1·28, P¼0·50). Ca supplements without co-administered vitamin
D did not alter total cancer risk over 4 years, although the meta-analysis lacked power to detect very small effects, or those with a
longer latency.
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It is possible that Ca intake has an impact on cancer risk,
with some observational studies suggesting that high intakes
of Ca and/or vitamin D are associated with a reduced risk of
colorectal(1–3) and breast cancer(4,5), and an increased risk of
prostate cancer(6–8); however, these results are not consist-
ent(9–14). To date, few randomised, placebo-controlled trials
of Ca supplements with or without vitamin D have reported
cancer outcomes. In a 4-year fracture prevention trial, Lappe
et al.(15) reported that Ca monotherapy decreased total cancer
risk by 47 % (P¼0·06), and Ca with vitamin D by 60 % (P¼0·01).
In contrast, three randomised, placebo-controlled trials(16–19)
of Ca with or without vitamin D have found no evidence of an
effect on cancer risk. We found no effect of Ca monotherapy
on total cancer incidence in a 5-year trial in postmenopausal
women(19). The Randomised Evaluation of Calcium Or
Vitamin D (RECORD) investigators found no effect of Ca
with or without vitamin D on cancer mortality or incidence
in older people treated for a median of 45 months(16). The
Women’s Health Initiative (WHI) investigators reported no
effect of Ca plus vitamin D on the risk of colorectal(18) or
breast(17) cancer in .36 000 postmenopausal women treated
for an average of 7 years. However, we recently reanalysed
the publicly available WHI dataset and found significant inter-
actions between treatment allocation, personal Ca or vitamin
D supplement use and the risk of total, breast and colorectal
cancers, suggesting that widespread personal (non-protocol)
supplement use may have obscured a therapeutic effect of
Ca and vitamin D on cancer endpoints(20). When analyses
*Corresponding author: M. J. Bolland, fax þ64 9 373 7677, email m.bolland@auckland.ac.nz
Abbreviations: RECORD, Randomised Evaluation of Calcium Or Vitamin D; WHI, Women’s Health Initiative.
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were restricted to participants not taking personal Ca or
vitamin D at baseline, Ca and vitamin D significantly reduced
the risk of total and breast cancer by 14–20 %, and non-
significantly reduced the risk of colorectal cancer by 17 %.
Thus, there is some evidence that Ca and vitamin D
supplements might lower cancer risk; however, it remains
uncertain whether these possible effects are related to Ca,
vitamin D or the combination of both agents. We have updated
a large database of randomised clinical trials of Ca supplements
in older adults, originally assembled to assess the effect of
Ca supplements on cardiovascular risk, to determine whether
Ca used as a monotherapy has an impact on cancer risk.
Methods
In November 2007, Medline, Embase and Cochrane Central
were searched for randomised, placebo-controlled trials of
Ca supplements, using the terms ‘calcium’, ‘randomised con-
trolled trial’ and ‘placebo’ as text words, and corresponding
Medical Subject Headings (MeSH) terms. The reference lists
of meta-analyses published between 1990 and 2007 on the
effect of Ca supplements on fracture, bone density, colorectal
neoplasia and blood pressure, and two clinical trial registries
(ClinicalTrials.gov and Australian New Zealand Clinical Trial
Registry) were searched. No language restrictions were
applied(21). In February 2012, searches of the electronic data-
bases were updated (Medline: 1966–February 2012; Embase:
1980–February 2012; Cochrane Central: January 2012).
Study selection
Studies were included if they were randomised, double-blind,
placebo-controlled trials; the mean age of participants at base-
line was .40 years; a dose of $500 mg/d of elemental Ca was
administered; $100 participants were randomised; partici-
pants of either sex were studied; and the duration of the
trial was .1 year. Studies were excluded if Ca and vitamin
D were co-administered and compared with placebo (studies
were eligible if vitamin D was given to both intervention and
control groups); if Ca was administered in the form of a com-
plex nutritional supplement or as a dietary modification; and
if most participants had a major systemic disease other than
osteoporosis or colorectal adenoma.
Search results
For the present review, two investigators carried out the
search (M. J. B. and S. M. B.) and two investigators indepen-
dently reviewed all potential studies (M. J. B. and A. G.) to
determine the adequacy of randomisation, the concealment
of allocation, the blinding of participants and investigators
and the extent of loss to follow-up.
Data description
The lead author of each eligible trial was invited to provide
patient-level data for cancer outcomes for their study. When
such data were not available, we requested trial-level
summary data. Complete trial-level data were available on total
cancer events for seven studies (9447 participants)(15,22–27), on
colorectal cancer for eight studies (9863 participants)(15,22–28),
on breast cancer for six studies (7641 participants)(15,22–26), on
prostate cancer for three studies (1806 participants)(23,25,27) and
on cancer-related mortality for six studies (8109 partici-
pants)(22,23,25–28). Partially complete trial-level data were available
on total cancer for a further three studies (1049 participants)(28–30),
and on colorectal and breast cancer for a further two studies (633
participants)(29,30). Of the studies that supplied complete trial-level
data, patient-level data were also available on total cancer and col-
orectal cancer events for four studies (7221 participants)(22,25–27),
on breast cancer events for three studies (6087 partici-
pants)(22,25,26) and on prostate cancer events for two studies
(1134 participants)(25,27). No data on cancer events were available
for six studies (2743 participants)(31–36).
We therefore had complete trial-level data on total cancer
events for 71 % of participants, at least partially complete
trial-level data for 79 % of participants, patient-level data for
54 % of participants and no data for 21 % of participants,
from sixteen eligible trials.
Ascertainment of cancer events
For seven studies, data on cancer events were supplied by
the lead authors. Data were obtained from a combination
of self-reports, hospital discharge data and death certifi-
cates(22,24–27,29,30) and cancer registries(25). For one study, data
on prostate cancer(37) and colorectal cancer(23) were obtained
Reports of studies identified by initial search (n 12 732) 
Reports of potentially relevant studies identified and
screened for retrieval (n 206) 
Reports of studies excluded (n 174)
  Study size <100 (n 118)
  Duration ≤12 months (n 30)
  Study design (n 26) 
Studies eligible for inclusion (n 16) 
Studies excluded as data on cancer
events not available (n 6)
Studies with trial-level data on cancer events (n 10) 
Studies with patient-level data on cancer events (n 4) 
Fig. 1. PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) flow chart of studies. The initial search was in November
2007 with 9358 reports identified, 173 reports of potentially relevant studies
retrieved, 150 reports excluded and twenty-three reports of fifteen individual
studies identified. The search was updated in March 2010 and February
2012: a further 3374 reports were identified, thirty-three reports retrieved and
one new study identified.
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Table 1. Characteristics of the sixteen studies eligible for inclusion in the meta-analysis
Studies
Ca-only
group (n)
Control
group (n)
Daily dose and
supplement type
Trial duration
(years)
Primary endpoint in the
original trial
Baseline mean
age (years) Female (%)
Patient-level data on cancer outcomes
Reid et al.(22) 68 67 1 g lactogluconate–carbonate 4 Bone mineral density 58 100
Grant et al.(16,25) 2617 2675 1 g carbonate 4* Low trauma fracture 77 85
Reid et al.(19,26) 732 739 1 g citrate 5 Clinical fracture 74 100
Reid et al.(27) 216 107 0·6 or 1·2 g citrate 2 Spine bone mineral density 56 0
Subtotal/average† 3633 3588 – 4·1 – 75·5 87·1
Trial-level data on cancer outcomes‡
Riggs et al.(30) 119 117 1·6 g citrate 4 Bone mineral density 66 100
Baron et al.(23,37) 464 466 1·2 g carbonate 4 Recurrence of colorectal adenoma 61 28
Bonithon-Kopp et al.(28) 204 212 2 g lactogluconate–carbonate 3 Recurrence of colorectal adenoma 59 37
Lappe et al.(15) 445 288 1·4 g citrate or 1·5 g carbonate 4 Fracture incidence 67 100
Bonnick et al.(24) 282 281 1·25 g carbonate 2 Spine bone mineral density 66 100
Chailurkit et al.(29) 201 196 0·5 g carbonate 2 PTH and bone mass 66 100
Subtotal/average† 1715 1560 – 3·3 – 63·7 67·8
Total/average† 5348 5148 – 3·9 – 72·3 82·0
No data on cancer outcomes
Smith et al.(32) 84 85 1·5 g carbonate 4 Arm bone mineral density 51 100
Dawson-Hughes et al.(36) 238 123 0·5 g carbonate or citrate 2 Spine bone mineral density 58 100
Elders et al.(33) 198 97 1 or 1·2 g lactogluconate
–carbonate or citrate
2 Spine bone mineral density NA 100
Recker et al.(34) 95 102 1·2 g carbonate 4 Vertebral fracture 74 100
Peacock et al.(31) 126 135 0·75 g citrate 4 Hip bone mineral density 76 72
Prince et al.(35) 730 730 1·2 g carbonate 5 Osteoporotic fracture 75 100
Subtotal/average† 1471 1272 – 4·1 – 68·5 97·4
PTH, parathyroid hormone; NA, not available.
* Mean duration was 45 months, with all participants followed for at least 2 years during the trial.
† Weighted by person-years of follow-up.
‡ Complete trial-level data on total cancer events were available for seven studies(15,22–27) and partially complete trial-level data were available for three studies(28–30).
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from published data, and data on total cancer, breast cancer and
cancer mortality were supplied by the lead author and derived
from hospital discharge data and death certificates. For another
study, data on colorectal cancer were obtained from published
data(28), and data on cancer-related mortality were supplied by
the lead author and derived from physician-reported cause of
death. For the final study, data on total, breast and colorectal
cancers were obtained from published data(15). The lead authors
provided a description of each type of cancer events, and cancers
described as ‘skin’, ‘epidermal/epidermoid’ or ‘basal cell’ or the
International Classification of Diseases (ICD) code C44 were
not considered in these analyses. For the one study for which
total cancer events were obtained from published data(15), the
authors reported only total non-skin cancers. When data on
cancer events were obtained from published data, data were
extracted independentlyby two investigators (M. J.B. andS.M.B.).
Endpoints
The pre-specified primary endpoint was the incidence of first
total cancer, excluding non-melanoma skin cancers. Second-
ary endpoints were the incidence of colorectal cancer, breast
cancer, prostate cancer and cancer-related mortality.
Statistical analysis
The primary analysis was of trial-level data. Statistical hetero-
geneity was assessed using Cochran’s Q statistic (P,0·10)
and the I 2 statistic (I 2 . 50 %). No significant statistical hetero-
geneity existed between trials in any of the analyses. Trial-
level summary data were pooled using DerSimonian and
Laird random-effects meta-analyses. Publication bias was
assessed using funnel plots. Analyses were carried out using
SAS version 9.2 or Review Manager 5.1 (The Nordic Cochrane
Centre, The Cochrane Collaboration, 2011). All tests were two-
tailed and P,0·05 was considered as significant.
Studies that also provided patient-level data were included
in a secondary patient-level analysis. Each endpoint was
analysed using a Cox proportional hazards model stratified
by study, and the hazard ratio (HR) and 95 % CI reported.
The assumption of proportional hazards was explored graphi-
cally and by carrying out a test for proportionality of the inter-
action between variables included in the model and the
logarithm of time. Assessment of the effect-modifying influ-
ence of covariates on outcomes was done by repeating the
models including the following covariates potentially associ-
ated with cancer incidence: age, sex, smoking status, BMI
and weight. This was also done by undertaking subgroup ana-
lyses using interaction terms between treatment allocation and
the following pre-specified subgroups: sex, age ($75 or ,75
years), dietary Ca (above or below the median for all studies),
serum 25-hydroxyvitamin D ($50 or ,50 nmol/l) and sup-
plement type (citrate, carbonate or lactogluconate–carbon-
ate), where data were available for .80 % of participants.
Based on the assumption that cancers diagnosed early on in
the trials may have been present, but undetected, at baseline,
we repeated these models including latent periods of 1 and 2
years. As a sensitivity analysis, the models were repeated
including only the trials in which data were obtained from
unverified sources (self-reports) or verified sources (cancer
registries).
Results
The results of the literature search are shown in Fig. 1, and the
characteristics of the eligible studies in Table 1. All ten eligible
studies providing data were randomised, double-blind, pla-
cebo-controlled trials. The method of randomisation was
stated in six trials: one used a centralised randomisation ser-
vice and five used computer-generated random numbers.
Allocation concealment was explicitly stated by four trials.
Details of participants who were lost to follow-up or withdrew
were reported by nine trials. All ten trials reported compli-
ance; however, the definitions of compliance differed and
were not always comparable. Table 2 shows the selected base-
line characteristics of participants.
Table 2. Baseline variables in the trials with patient- or trial-level data available for cancer outcomes
(Mean values and standard deviations)
Studies
Dietary Ca
(mg/d)
25-Hydroxyvitamin
D (nmol/l) Weight (kg) BMI (kg/m2)
Current
smoker (%)
History of
colorectal
adenoma (%)Mean SD Mean SD Mean SD Mean SD
Reid et al.(22) 750 290 93 37 65 9 25 3 10 NA
Riggs et al.(30) 710 290 80 25 NA NA NA NA
Baron et al.(37) 880 440 73 27 82 15 27 4 19 100
Bonithon-Kopp et al.(28) 980 380 NA NA NA NA 100
Grant et al.(25)* 820 350 38 16 65 12 NA 12 NA
Reid et al.(26) 860 390 54 18 67 11 26 4 3 NA
Reid et al.(27) 870 450 92 33 83 12 26 3 3 NA
Lappe et al.(15) 1070† 72 20 77 15 29 6 NA NA
Bonnick et al.(24) 1240 580 NA NA NA 0·4 NA
Chailurkit et al.(29) 375 210 69 19 59 8 25 3 NA NA
NA, not available.
* 25-Hydroxyvitamin D measured in a sample of sixty participants.
† Value is median.
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Trial-level analysis
There were seven studies that provided complete trial-level
data on total cancer events and were included in the primary
analysis. The number of people with cancer events in each
study by treatment allocation is shown in Table 3, and the
results of the trial-level analysis are shown in Fig. 2. Allocation
to Ca supplements had no effect on the risk of total cancer,
colorectal cancer, breast cancer or cancer-related mortality.
Allocation to Ca supplements was associated with a significant
decrease in the risk of prostate cancer. A further three
trials(28–30) for total cancer and two trials(29,30) for colorectal
and breast cancer had data only for subgroups of participants,
and were included in a sensitivity analysis that included data
from all ten trials. Including data from these further trials did
not change the results for any endpoint. Publication bias
was not evident on inspection of funnel plots in any analysis.
Patient-level analysis
Among the eligible trials, four studies that provided trial-level
data also provided patient-level data and were included in a
secondary patient-level analysis. The selected baseline charac-
teristics are shown in Table 4, and the results in Table 5 and
Fig. 3. The median duration of follow-up in both groups
was 3·5 (interquartile range 2·6–4·4) years. Allocation to Ca
supplements had no effect on the risk of total cancer, breast
cancer or cancer-related mortality. Allocation to Ca sup-
plements significantly increased the risk of colorectal cancer,
and non-significantly decreased the risk of prostate cancer.
Adjusting for pre-specified covariates likely to be related to
cancer outcomes, with data available for more than 80 % of
participants (age, sex, smoking status and weight), did not
change these results, nor did including trials in which data
were obtained only from verified sources. Repeating the
models including a latent period of 1 or 2 years to attempt
to adjust for cancers that were present, but undetected at base-
line, moved the results for colorectal cancer and prostate
cancer towards significance, but did not alter the results in
any other way (Table 5). In pre-specified subgroup analyses,
no interactions were identified between treatment allocation
and age, sex, vitamin D status, smoking status, dietary Ca
intake and supplement type for any cancer endpoint.
Discussion
In the present meta-analysis of 10 500 participants from ten
trials, Ca supplements without co-administered vitamin D
did not alter the risk of total cancer, breast cancer or cancer-
related mortality over 4 years. Ca supplements significantly
reduced prostate cancer risk; however, this was based on a
small number of events. Ca supplements did not alter
colorectal cancer risk in the trial-level analysis, while there was
an increased risk in the patient-level analysis; however, this was
based on a small number of events. Including a latent period of
1 or 2 years did not meaningfully alter the results.
While the association between Ca intake and cancer risk
has been the subject of numerous observational studies, few T
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randomised, placebo-controlled trials of Ca supplements have
examined cancer incidence as an outcome and none as a pri-
mary endpoint. In a 4-year trial of 1179 postmenopausal
women, Lappe et al.(15) reported a non-significant
47 % reduction in total cancer risk with Ca monotherapy,
and a significant 60 % reduction with Ca plus vitamin
D. There was no reduction in risk with Ca plus vitamin D
compared with Ca monotherapy (P¼0·46), suggesting that
Ca supplements were responsible for the protective effects.
We were unable to confirm reductions in cancer risk with
Total
Reid et al.(27)
Lappe et al.(15)
Bonnick et al.(24)
Reid et al.(26)
Grant et al.(23) VitD
Grant et al.(25)
Baron et al.(23)
Reid et al.(22)
RR of total cancer
(95% CI)Study
0·5 1 2 30·8 1·2 1·50·3 5
RR 0·95 (95% CI 0·76,1·18) P =0·63I2= 26%
Total
Bonnick et al.(24)
Lappe et al.(15)
Reid et al.(26)
Grant et al.(25) Vit D
Grant et al.(25)
Bonithon-Kopp et al.(28)
Baron et al.(23)
Reid et al.(22)
9·6
1·9
16·6
2·1
RR of colorectal cancer
(95% CI)Study
0·5 1 2 30·8 1·2 1·50·3 5
RR 1·38 (95% CI 0·89,2·15) P =0·15I2= 0%
Total
Lappe et al.(15)
Bonnick et al.(24)
Reid et al.(26)
Grant et al.(25) VitD
Grant et al.(25)
Baron et al.(23)
Reid et al.(22)
RR of breast cancer
(95% CI)Study
0·5 1 2 30·8 1·2 1·50·3 5
RR 1·01 (95% CI 0·64,1·59) P =0·97I2= 12 %
Total
Reid et al.(27)
Grant et al.(25) VitD
Grant et al.(25)
Baron et al.(23)
RR of prostate cancer
(95% CI)Study
0·5 1 2 30·8 1·2 1·50·3 5
RR 0·54 (95% CI 0·30,0·96) P =0·03I2= 0%
Total
Reid et al.(26)
Grant et al.(25) VitD
Grant et al.(25)
Bonithon-Kopp et al.(28)
Baron et al.(23)
1·6
12·0
27·7
27·5
18·6
2·4
9·7
0·5
2·6
24·5
40·6
2·1
2·0
2·4 
25·9
23·7
2·2
16·1
27·8
50·4
23·7
22·6
3·3
6·9
3·5
45·3
38·2
6·1
1·97
0·67
1·14
0·93
1·11
1·99
0·55
0·17
0·99
0·60
0·35
2·18
1·58
1·18
0·13
4·98
0·33
0·13
1·29
1·57
4·98
0·49
0·96
0·57
0·52
0·59
0·17
0·78
1·04
1·00
0·94
1·01
0·37, 10·40
0·39, 1·16
0·86, 1·51
0·70, 1·24
0·74, 1·66
0·50, 7·89
0·29, 1·03
0·01, 4·04
0·06, 15·43
0·14, 2·51
0·01, 8·45
0·89, 5·32
0·79, 3·17
0·40, 3·49
0·13, 2·69
0·24, 103·31
0·01, 7·92
0·01, 2·38
0·59, 2·83
0·68, 3·61
0·24, 103·31
0·17, 1·38
0·45, 2·02
0·25, 1·28
0·16, 1·68
0·17, 1·97
0·01, 4·04
0·29, 2·08
0·26, 4·10
0·68, 1·46
0·62, 1·42
0·36, 2·86
RR of cancer-related
mortality (95% CI) Weight (%) 95% CIRR
Weight (%) 95% CIRR
Weight (%) 95% CIRR
Weight (%) 95% CIRR
Weight (%) 95% CIRR
Study
0·5 1 2 30·8 1·2 1·50·3 5
RR 0·96 (95% CI 0·74,1·24) P =0·75I2= 0%
Favours Ca Favours control
Fig. 2. Random-effects models of calcium supplementation on cancer events and cancer mortality. Full trial-level data were available for eight studies for colorec-
tal cancer and six studies for cancer mortality. However, some studies are not shown as no events occurred: there were no colorectal cancer events in the study
by Reid et al.(27) and was no cancer-related mortality in the study by Reid et al.(22) or Reid et al.(27). Grant et al.(25) is the calcium v. placebo arms of this study,
and Grant et al.(25) vitamin D (VitD) is the calcium plus VitD v. VitD-only arms. RR, relative risk.
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Ca monotherapy over an equivalent 4-year period in the pre-
sent meta-analysis, with consistent findings in both trial- and
patient-level analyses. Compared with the Lappe trial, the
population in the present meta-analysis was older (72 v. 67
years), but had a lower annualised incidence of cancer in
the control group (1·4 v. 1·7 %), suggesting that the positive
findings in the Lappe trial might have resulted from an unex-
plained high rate of cancer in the control group(38), and a
small number of total cancer events (n 50, compared with
550 in the present meta-analysis). It is also possible that the
Lappe trial results are an outlying result that might have
arisen by chance.
Consistent with the present meta-analysis, a recent
analysis of the RECORD study(16), a trial of 5292 older
people randomised to Ca, vitamin D, Ca with vitamin D or
placebo for a median duration of 45 months and followed
for a further 3 years, found no effect of Ca (with or without
vitamin D) on the risk of total cancer incidence or
cancer-related mortality.
A protective effect of Ca with vitamin D supplements
against total cancer, breast cancer and possibly colorectal
cancer was suggested in a recent reanalysis of WHI data(20).
As Ca and vitamin D were administered together in that trial,
it was not possible to determine which agent was responsible
for the protective effects. The results of the present meta-
analysis suggest that Ca supplements for 4 years without
co-administered vitamin D have no effect on the risk of total
cancer, which might indicate that vitamin D, or a combination
of both agents, was responsible for the observed reduction
in risk in the WHI reanalysis. However, it is also possible
that the present meta-analysis lacked sufficient power and/or
was of too short duration to detect a small effect of Ca on
total cancer risk, though the beneficial trends in the WHI
were apparent from year 2. The total cancer endpoint in the
WHI reanalysis was based on 1300 cancer events over
7 years among 15 600 women, whereas in the present meta-
analysis, there were 550 cancer events over 4 years among
10 500 men and women. The lack of an effect of Ca on total
cancer in the present meta-analysis suggests that if Ca does
have an effect on total cancer risk, it is small. Future trials
should use estimates from these meta-analyses to calculate
sample sizes: such trials will need to be large and of a long
duration. The design of such trials is discussed in detail in
the description of a large trial of vitamin D and n-3 for
cancer and cardiovascular prevention(39).
In contrast with earlier observational studies(1–3) and
colorectal adenoma chemoprevention trials(23,40), we found
no evidence that Ca monotherapy reduces colorectal cancer
risk. This may have been due to the duration of the trials:
if colorectal cancer has a latency period of 10–20 years,
Table 4. Baseline characteristics of participants in four studies included
in the patient-level analysis by treatment allocation
(Mean values and standard deviations; medians and interquartile
ranges; percentages)
Ca group
(n 3633)
Placebo group
(n 3588)
Characteristics Mean SD Mean SD
Age (years)
Median 75·2 75·6
Interquartile range 72–80 72–80
Women (%)* 83·0 85·6
Caucasian (%) 99·1 99·4
Weight (kg) 66·5 12·9 66·2 12·7
Dietary Ca (mg/d) 830 366 827 362
25-Hydroxyvitamin D (nmol/l)† 63·6 28·8 60·7 28·0
Current smoker (%) 9·9 9·1
* Proportion of women was significantly higher in the placebo group because one
study that only involved men had a 2:1 ratio of allocation to Ca or placebo. No
other differences existed between groups.
† Data available from four studies for 1050 participants in the Ca group and 952
participants in the placebo group.
Table 5. Results of the patient-level analysis†
(Hazard ratios and 95 % confidence intervals)
Ca (n 3633) Placebo (n 3588) Hazard ratio 95 % CI P
Total events
Total cancer 227 221 1·07 0·89, 1·28 0·50
Colorectal cancer 43 27 1·63 1·01, 2·64 0·046*
Breast cancer 41 35 1·27 0·81, 2·02 0·30
Prostate cancer 8 16 0·49 0·21, 1·14 0·10
Cancer-related mortality 98 103 0·98 0·74, 1·29 0·86
1-year latent period‡
Total cancer 172 160 1·12 0·90, 1·39 0·30
Colorectal cancer 34 19 1·84 1·05, 3·22 0·03*
Breast cancer 33 25 1·47 0·86, 2·51 0·15
Prostate cancer 4 11 0·34 0·11, 1·08 0·07
Cancer-related mortality 77 75 1·05 0·77, 1·45 0·75
2-year latent period§
Total cancer 112 96 1·24 0·94, 1·63 0·13
Colorectal cancer 19 14 1·39 0·70, 2·77 0·35
Breast cancer 22 17 1·51 0·78, 2·90 0·22
Prostate cancer 3 4 0·74 0·17, 3·31 0·69
Cancer-related mortality 49 42 1·2 0·79, 1·81 0·39
*P,0·05.
† Number of people with cancer events.
‡ Events during the first year censored.
§ Events during the first and second year censored.
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participants diagnosed during each trial may have had
early-stage cancer that was present but asymptomatic and
undetected at baseline. While Ca may inhibit colorectal
cancer initiation, such as adenoma formation(23), little research
has examined its effects on cancer progression. In polyp-bear-
ing participants, Ca and antioxidants had no effect on existing
adenoma growth, but significantly reduced new adenoma
development over 3 years(40). The present meta-analysis
included two trials that had participants with a history of col-
orectal adenoma. Because of the small number of colorectal
cancer events in these trials (three in the combined Ca
groups and six in the combined control groups), we were
unable to investigate whether the effect of Ca on colorectal
cancer was different in these participants.
We found some evidence of increased colorectal cancer risk
with Ca, although this was only statistically significant in the
patient-level analysis. The increased risk may have resulted
from increased screening for colorectal cancer in the group
allocated to Ca, as a change in bowel habits is an early
symptom of colorectal cancer(41), and Ca supplements cause
gastrointestinal side effects(26,42). While the increased risk
could reflect an effect of Ca on colorectal cancer progression,
the small number of colorectal cancer events and the lack of
statistical significance in the primary trial-level analysis suggest
that it might be a chance finding.
We observed a reduction in prostate cancer risk with Ca in
the primary trial-level analysis, largely based on two trials(25,37)
(in a third trial, only one prostate cancer event occurred(27)).
The risk estimate derived from the patient-level analysis was
similar, although not statistically significant, probably because
there were 50 % fewer events than in the trial-level analysis. In
a more detailed analysis of one of these trials(37), Ca had no
effect on prostate cancer risk over 10 years (4 years of treat-
ment and 6 years of post-treatment follow-up), but reduced
risk by 48 % during the first 6 years. These results suggest
that the positive association between Ca intake and increased
prostate cancer risk, suggested by some(6–8) but not all(12,13)
observational studies, may be unrelated to Ca, and instead
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3588 3411 3154 2324 1280 387
Ca 3017 2846 2686 2039 1177 372
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Not at risk
Not at risk
Ca
Placebo 
Ca
Placebo3070 2929 2753 2090 1195 391
616 576 420 212
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Fig. 3. Cumulative incidence of (a) total cancer (hazard ratio (HR) 1·07, 95 % CI 0·89, 1·28, P¼0·50), (b) colorectal cancer (HR 1·63, 95 % CI 1·01,
2·64, P¼0·046), (c) breast cancer (HR 1·27, 95 % CI 0·81, 2·02, P¼0·30) and (d) prostate cancer (HR 0·49, 95 % CI 0·21, 1·14, P¼0·098) in four studies that
contributed patient-level data. , Ca; , placebo.
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due to other factors correlated with Ca intake, such as dairy
product intake, or may have occurred from residual confound-
ing. The small number of prostate cancer events means that
the present findings should be interpreted cautiously, but
if Ca does protect against prostate cancer, this could be
mediated through the Ca-sensing receptor, found on prostate
cells(43), or indirectly through parathyroid hormone, which
has been implicated in prostate carcinogenesis(44).
The present meta-analysis has some limitations. Cancer was
not a primary outcome of any included study, and cancer
events were not collected in a standardised manner. However,
unless there was a differential misclassification or misreporting
of cancer events in people allocated to Ca (as we suggested
for colorectal cancer), this should not have affected the pre-
sent results. No data for cancer events were available for six
trials comprising 20 % of participants. With one exception,
these trials were small, and the consistency of the findings
suggests that the addition of these trials would not have
affected the present results.
In summary, we found no evidence that Ca supplements
without co-administered vitamin D influence total cancer
risk over 4 years. The differences between the findings of
the present meta-analysis and those of a recent reanalysis of
the WHI, suggesting the benefits of co-administered Ca and
vitamin D on cancer incidence, might be attributable to the
co-administration of vitamin D in that trial. However, we
cannot rule out that the present meta-analysis lacked sufficient
power or that the duration of trials was too short to detect a
small effect of Ca supplements. Any future trials of Ca sup-
plements on cancer incidence should base sample size calcu-
lations on the effect sizes observed here. Such trials will need
to be very large and of a long duration.
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